Next Article in Journal
Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma
Next Article in Special Issue
Role and Merits of Green Based Nanocarriers in Cancer Treatment
Previous Article in Journal
Experimental Validation of the MRcollar: An MR Compatible Applicator for Deep Heating in the Head and Neck Region
Previous Article in Special Issue
A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy
Review

Lipid Nanocarriers for Hyperproliferative Skin Diseases

1
CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
2
Faculty of Pharmaceutical Sciences, São Paulo State University (UNESP), Campus of Araraquara, Rodovia Araraquara Jaú, Araraquara 14800-903, SP, Brazil
3
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08007 Barcelona, Spain
4
Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08007 Barcelona, Spain
5
Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland
6
Department of Hypertension Angiology and Internal Medicine, Poznań University of Medical Sciences, 61-701 Poznań, Poland
7
Department of Environmental Medicine, Poznań University of Medical Sciences, 61-701 Poznań, Poland
8
Department of Gastroenterology, Dietetics and Internal Diseases, H. Swiecicki University Hospital, Poznań University of Medical Sciences, 60-355 Poznań, Poland
*
Authors to whom correspondence should be addressed.
Academic Editors: Maciej Wnuk and Anna Lewinska
Cancers 2021, 13(22), 5619; https://doi.org/10.3390/cancers13225619
Received: 6 October 2021 / Revised: 5 November 2021 / Accepted: 5 November 2021 / Published: 10 November 2021
Different drugs, including antiproliferative and corticosteroids in general, are recommended for the treatment of hyperproliferative skin diseases (HSD). The effectiveness of many of these drugs is limited due to their low solubility in water and low penetration in the skin. The loading of these drugs in lipid nanocarriers, such as lipid nanoparticles and liposomes, has been considered as a successful solution to improve the drug bioavailability through the skin, to control their release kinetics and thus reduce the risk of potential side effects. In this work, we discuss the use of lipid nanocarriers loading drugs against HSD.
Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. View Full-Text
Keywords: lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancer lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancer
Show Figures

Figure 1

MDPI and ACS Style

Souto, E.B.; de Souza, A.L.R.; dos Santos, F.K.; Sanchez-Lopez, E.; Cano, A.; Zielińska, A.; Staszewski, R.; Karczewski, J.; Gremião, M.P.D.; Chorilli, M. Lipid Nanocarriers for Hyperproliferative Skin Diseases. Cancers 2021, 13, 5619. https://doi.org/10.3390/cancers13225619

AMA Style

Souto EB, de Souza ALR, dos Santos FK, Sanchez-Lopez E, Cano A, Zielińska A, Staszewski R, Karczewski J, Gremião MPD, Chorilli M. Lipid Nanocarriers for Hyperproliferative Skin Diseases. Cancers. 2021; 13(22):5619. https://doi.org/10.3390/cancers13225619

Chicago/Turabian Style

Souto, Eliana B., Ana L.R. de Souza, Fernanda K. dos Santos, Elena Sanchez-Lopez, Amanda Cano, Aleksandra Zielińska, Rafał Staszewski, Jacek Karczewski, Maria P.D. Gremião, and Marlus Chorilli. 2021. "Lipid Nanocarriers for Hyperproliferative Skin Diseases" Cancers 13, no. 22: 5619. https://doi.org/10.3390/cancers13225619

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop